Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial

被引:73
|
作者
Azizi, Fereidoun [1 ]
Amouzegar, Atieh [1 ]
Tohidi, Maryam [2 ]
Hedayati, Mehdi [3 ]
Khalili, Davood [2 ,4 ]
Cheraghi, Leila [4 ]
Mehrabi, Yadollah [5 ]
Takyar, Miralireza [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, POB 19395-4763, Tehran 1985717413, Iran
[2] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Prevent Metab Disorders Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Cellular & Mol Endocrine Res Ctr, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Dept Epidemiol & Biostat, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Epidemiol & Biostat, Tehran, Iran
关键词
long-term; methimazole; Graves' disease; remission rates; ANTITHYROID DRUG-TREATMENT; HYPERTHYROIDISM; EXPOSURE; IODINE; RISK;
D O I
10.1089/thy.2019.0180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length methimazole therapy. We also sought variables associated with relapse following the latter. Methods: We enrolled 302 consecutive patients with untreated first episodes of Graves' hyperthyroidism. After 18-24 months of methimazole, 258 patients (85.4%) were randomized to an additional 36-102-month courses ("long-term group": n = 130; scheduled total time on methimazole: 60-120 months) or discontinuation of methimazole ("conventional group": n = 128). Patients were followed 48 months postmethimazole cessation. We performed Cox proportional hazards modeling to identify factors associated with relapse after conventional courses. Results: Methimazole was given for 95 +/- 22 months in long-term patients and 19 +/- 3 months in the conventional group. Fourteen patients experienced cutaneous reactions and 2 liver enzyme elevations during the first 18 months of treatment; no further methimazole-related reactions were observed despite therapy for up to another 118 months. Hyperthyroidism recurred within 48 months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877 CD28 polymorphism or the DQB1-05 HLA polymorphism were independently associated with relapse. Conclusion: Administration of low-dose methimazole for a total of 60-120 months safely and effectively treats Graves' hyperthyroidism, with much higher remission rates than those attained by using conventional 18-24-month courses.
引用
收藏
页码:1192 / 1200
页数:9
相关论文
共 50 条
  • [1] Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial
    Azizi, Fereidoun
    Takyar, Miralireza
    Madreseh, Elham
    Amouzegar, Atieh
    PEDIATRICS, 2019, 143 (05)
  • [2] Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study
    Benker, G
    Reinwein, D
    Kahaly, G
    Tegler, L
    Alexander, WD
    Fassbinder, J
    Hirche, H
    CLINICAL ENDOCRINOLOGY, 1998, 49 (04) : 451 - 457
  • [3] Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial
    Fereidoun Azizi
    Hengameh Abdi
    Atieh Amouzegar
    BMC Endocrine Disorders, 21
  • [4] Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial
    Azizi, Fereidoun
    Abdi, Hengameh
    Amouzegar, Atieh
    BMC ENDOCRINE DISORDERS, 2021, 21 (01)
  • [5] Effects of Low-dose Methotrexate With Methimazole in Patients With Graves' Disease: Results of a Randomized Clinical Trial
    Xie, Pu
    Shen, Liyun
    Peng, Rongguang
    Wang, Yanqiu
    Yin, Qinglei
    Chen, Xinxin
    Jin, Zhou
    Ning, Guang
    Wang, Weiqing
    Wang, Shu
    Zhou, Yulin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 110 (02): : 489 - 497
  • [6] The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: A randomized clinical trial
    Braga, M
    Walpert, N
    Burch, HB
    Solomon, BL
    Cooper, DS
    THYROID, 2002, 12 (02) : 135 - 139
  • [7] THYROID STIMULATING IMMUNOGLOBULINS IN PATIENTS IN LONG-TERM REMISSION AFTER GRAVES-DISEASE
    BLIDDAL, H
    BECH, K
    KIRKEGAARD, C
    HORMONE AND METABOLIC RESEARCH, 1984, 16 (11) : 602 - 605
  • [8] Medical therapy of Graves' disease:: effect on remission rates of methimazole alone and in combination with triiodothyronine
    Raber, I
    Kmen, E
    Waldhäusl, W
    Vierhapper, H
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (02) : 117 - 124
  • [9] Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial
    Leo, M.
    Bartalena, L.
    Dottore, G. Rotondo
    Piantanida, E.
    Premoli, P.
    Ionni, I.
    Di Cera, M.
    Masiello, E.
    Sassi, L.
    Tanda, M. L.
    Latrofa, F.
    Vitti, P.
    Marcocci, C.
    Marino, M.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2017, 40 (03) : 281 - 287
  • [10] Effects of selenium on short-term control of hyperthyroidism due to Graves’ disease treated with methimazole: results of a randomized clinical trial
    M. Leo
    L. Bartalena
    G. Rotondo Dottore
    E. Piantanida
    P. Premoli
    I. Ionni
    M. Di Cera
    E. Masiello
    L. Sassi
    M. L. Tanda
    F. Latrofa
    P. Vitti
    C. Marcocci
    M. Marinò
    Journal of Endocrinological Investigation, 2017, 40 : 281 - 287